Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 99 Thoracic 1 Other hematologic neoplasm 1 Head & Neck 1

Conditions

Salivary Gland Neoplasms 1

Interventions

Cisplatin 620 pembrolizumab 323 Radiotherapy 319 Cetuximab 275 Docetaxel 221 Radiotherapy, Intensity-Modulated 210 Carboplatin 197 Fluorouracil 196 Paclitaxel 159 Nivolumab 138 Gemcitabine 124 Magnetic Resonance Spectroscopy 94 Radiation 85 Drug Therapy 77 Capecitabine 76 toripalimab 75 Surgical Procedures, Operative 62 durvalumab 60 Biopsy 52 Cyclophosphamide 50 Chemoradiotherapy 47 camrelizumab 46 Specimen Handling 46 Erlotinib Hydrochloride 46 Radiosurgery 45 130-nm albumin-bound paclitaxel 44 Standard of Care 43 tislelizumab 42 Platinum 41 Bevacizumab 40

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × apalutamide × Head & Neck × Clear all

NCT04325828 2026-06-05

YATAGARASU

Janssen Pharmaceutical K.K.

Phase 2 Active not recruiting

31 enrolled 15 charts

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡